8-KOther Events

BOSTON SCIENTIFIC CORP 8-K Report (Jun 4, 2004)

Filed June 4, 2004For Securities:BSX

Summary

Boston Scientific Corporation (BSX) has filed an 8-K report to announce the completion of its acquisition of Advanced Bionics Corporation. This privately-held company, specializing in medical devices, was acquired for an initial cash payment of approximately $740 million. The transaction was funded through commercial paper issuance, indicating BSX's ability to access short-term financing for strategic growth initiatives. The acquisition structure includes a significant earnout component, with payments tied to future performance milestones based on net sales and profitability across Advanced Bionics' four key technology platforms: cochlear implants, implantable pulse generators, drug pumps, and bion microstimulators. This structure suggests BSX's confidence in the future growth potential of Advanced Bionics and aligns the interests of the sellers with the company's long-term success. Investors should monitor the performance of these platforms and the subsequent earnout payments as a key indicator of the acquisition's value realization.

Key Highlights

  • 1Boston Scientific Corporation (BSX) acquired Advanced Bionics Corporation, a privately-held medical device company.
  • 2The initial purchase price was approximately $740 million in cash.
  • 3The acquisition was funded through the issuance of commercial paper.
  • 4A substantial earnout mechanism is included, tied to future performance milestones based on net sales and profitability.
  • 5Earnout payments are segmented by Advanced Bionics' four principal technology platforms: cochlear implants, implantable pulse generators, drug pumps, and bion microstimulators.
  • 6The earnout horizon for performance milestones is 72 months.
  • 7Financial statements and pro forma information related to the acquisition will be filed via amendment within 60 days (by August 13, 2004).

Frequently Asked Questions

This 8-K filing announces the completion of Boston Scientific Corporation's acquisition of Advanced Bionics Corporation, providing key details about the transaction, including the purchase price and funding method.

The initial purchase price of approximately $740 million was funded through the issuance of commercial paper, which is a type of short-term, unsecured debt instrument.

An earnout is a provision in an acquisition agreement where part of the purchase price is contingent on the future performance of the acquired company. In this case, Boston Scientific will make additional payments to the sellers of Advanced Bionics based on achieving specific net sales and profitability targets across its technology platforms over a 72-month period.

Boston Scientific has stated that the required financial statements of Advanced Bionics and pro forma financial information will be filed as an amendment to this report no later than August 13, 2004.